Verastem Inc (FRA:2VSA)
€ 4.06 0.24 (6.28%) Market Cap: 193.89 Mil Enterprise Value: 145.66 Mil PE Ratio: 0 PB Ratio: 16.62 GF Score: 35/100

Q3 2019 Verastem Inc Earnings Call Transcript

Oct 29, 2019 / 08:30PM GMT
Release Date Price: €14.15 (-9.31%)
Operator

Good afternoon, and welcome to the Verastem Oncology third quarter financial results conference call on Tuesday October 29, 2019. (Operator Instructions) Please be advised that this call is being recorded at the company's request and will be available on the company's website for a period of 90 days from today.

At this time, I would like to introduce Mr. John Doyle, Vice President of Investor Relations and Finance at Verastem Oncology. Please go ahead.

John Doyle
Verastem, Inc. - VP of IR & Finance

Welcome, everyone, and thank you for joining us this afternoon to discuss Verastem Oncology's financial results and corporate update for the third quarter of 2019. I'm joined today by Brian Stuglik, Chief Executive Officer; Dan Paterson, President and Chief Operating Officer; and Rob Gagnon, Chief Financial and Business Officer.

During today's call, Brian will provide some opening comments and provide a corporate update, Dan will discuss a few clinical development highlights and then Rob will provide an overview of our third quarter financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot